Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Ondansetron Kabi, is a 5‑HT3 receptor antagonist presented as an intravenous solution for intravenous use. It is employed to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult patients.

GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Ondansetron Kabi is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy-induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes in cancer patients receiving emetogenic chemotherapy. - Radiotherapy-induced nausea and vomiting: helps prevent nausea associated with radiation treatment of the abdomen or pelvis. - Postoperative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures under general anesthesia.

Ondansetron Kabi may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Constipation: reduced bowel movements, may require laxative support. - Dizziness: sensation of light‑headedness, usually resolves after continued therapy. - Fatigue: general tiredness without specific cause.

Serious or Rare Side Effects: - QT prolongation: may predispose to ventricular arrhythmias, especially with other QT‑prolonging agents. - Anaphylaxis: severe allergic reaction with rash, swelling, and respiratory compromise. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic drugs.

Before initiating therapy with Ondansetron Kabi, consider the following safety measures.

- Assess cardiac risk: evaluate baseline ECG for QT interval prolongation. - Monitor electrolytes: correct hypokalemia or hypomagnesemia prior to administration. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant use with other QT‑prolonging agents: increased arrhythmia risk. - Pregnancy and lactation: weigh benefits against potential risks; consult obstetric guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ondansetron Kabi can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Other QT‑prolonging drugs (e.g., quinidine, haloperidol): may increase risk of cardiac arrhythmia. - Serotonergic agents (e.g., tramadol, SSRIs): risk of serotonin syndrome. - Apomorphine: may cause profound hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Aminoglycoside antibiotics: may potentiate QT prolongation.